Question · Q3 2026
Ted Jackson asked about the long-term impact of administration-driven spending and the onshoring of pharmaceutical manufacturing (e.g., Lilly, AstraZeneca, Amgen) on Transcat's organic growth, including the potential revenue opportunity from new plants. He also inquired about the similar effects of increased defense spending and CapEx by major contractors (e.g., Lockheed, RTX, Northrop). Finally, he questioned if these trends could recalibrate Transcat's organic growth rate to tick up beyond historical averages towards the end of the decade, and sought an update on the CEO search timeline and potential additional one-time expenses in Q4.
Answer
Lee Rudow, President and CEO, confirmed that any onshoring of manufacturing in regulated business spaces, including life sciences and defense, is beneficial for Transcat. He explained that Transcat can participate in multiple phases of capital projects, from plant building to recurring calibration, and that increased defense contracting in a highly regulated space is positive. Tom Barbato, CFO, added that more equipment from increased CapEx is good, with recurring calibration revenue being the ultimate goal. Lee Rudow noted that while high single-digit growth is consistent, double-digit growth has occurred and is not impossible, acknowledging the challenge of growing on a larger base but seeing no reason why high single-digit growth cannot be consistently achieved. Regarding the CEO search, Lee Rudow stated that a conclusion by the Q4 report is a reasonable expectation, with some additional expenses anticipated in Q4.
Ask follow-up questions
Fintool can predict
TRNS's earnings beat/miss a week before the call